Forced Vasohibin‐1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity
Cancer Reports · 2024
DOI: 10.1002/cnr2.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Takahiro Koyanagi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Microtubules, Cyclin B1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan.
Abstract (Originalsprache)
Background
Vasohibin‐1 (VASH1), an angiogenic inhibitor, exhibits tubulin carboxypeptidase activity, which is involved in microtubule functions. Paclitaxel, the core chemotherapeutic agent for ovarian cancer chemotherapy, has a point of action on microtubules and may interact with VASH1.
Aims
To examine the influence of VASH1 on intracellular tubulin detyrosination status, cyclin B1 expression, and paclitaxel chemosensitivity using VASH1‐overexpressing ovarian cancer cell lines. Methods and Results Gene‐transfected human ovarian cancer cell lines were subjected to western blot analysis. Western blot analysis of VASH1‐overexpressing ovarian cancer cells revealed upregulated expression of detyrosinated tubulin and cyclin B1 compared with control cells. By WST‐1 assay, paclitaxel chemosensitivity of VASH1‐overexpressing ovarian cancer cells was markedly enhanced compared with that of control cells, whereas there was no significant difference in chemosensitivity to cisplatin. The forced expression of VASH1 enhanced tubulin carboxypeptidase activity and increased cyclin B1 expression, resulting in augmented paclitaxel chemosensitivity in ovarian cancer cells.
Conclusion
Ovarian cancer treatment strategies targeting VASH1 can potentiate the effects of conventional chemotherapy by inhibiting angiogenesis and regulating microtubule activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
- Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
ORCID-Profile: Takahiro Koyanagi
Förderung
- Ministry of Education, Culture, Sports, Science and Technology of Japan
Zitieren
APA
Koyanagi, T., Saga, Y., Takahashi, Y., Tamura, K., Takahashi, S., Taneichi, A., Takei, Y., Mizukami, H., & Fujiwara, H. (2024). Forced Vasohibin‐1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity. Cancer Reports. https://doi.org/10.1002/cnr2.70100
Vancouver
Koyanagi T, Saga Y, Takahashi Y, Tamura K, Takahashi S, Taneichi A, et al. Forced Vasohibin‐1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity. Cancer Reports. 2024. doi:10.1002/cnr2.70100
BibTeX
@article{Koyanagi2024,
author = {Koyanagi, Takahiro and Saga, Yasushi and Takahashi, Yoshifumi and Tamura, Kohei and Takahashi, Suzuyo and Taneichi, Akiyo and Takei, Yuji and Mizukami, Hiroaki and Fujiwara, Hiroyuki},
title = {Forced Vasohibin‐1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.70100}
}
EUVIMED